About: Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Sector: Healthcare
Industry: Medical Devices
Latest price: $0.43 (+5.03%)
LUCD NASDAQ Lucid Diagnostics Inc
Lucid Diagnostics Inc share price
Atividade de preço de LUCD
Último preço
$ 0,430
Variação (24h)
0,02 USD (5,03%)
Volume
4.99M
Volume (média 4 sem.)
-
Abertura
$ 0,41
Variação do dia
$ 0,40 - $ 0,46
Fechamento anterior
$ 0,41
Último negócio
29 Oct, 8:24 pm GMT+0
Atrasado
29 Oct, 8:24 pm GMT+0
LUCD price performance
Atrasado
29 Oct, 8:24 pm GMT+0
quote.marketSignals